---
title: "LEGN.US (LEGN.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LEGN.US/news.md"
symbol: "LEGN.US"
name: "LEGN.US"
parent: "https://longbridge.com/en/quote/LEGN.US.md"
datetime: "2026-05-19T20:34:56.402Z"
locales:
  - [en](https://longbridge.com/en/quote/LEGN.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LEGN.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LEGN.US/news.md)
---

# LEGN.US (LEGN.US) — Related News

### [3 Best Healthcare Stocks to Buy in May 2026, According to Analysts](https://longbridge.com/en/news/286619134.md)
*2026-05-15T21:28:05.000Z*
> Healthcare stocks are back in focus this month as investors look for strong pipelines and steady growth in a market stil

### [Legend Biotech (LEGN) Q1 Loss Persists And Tests Bullish Profitability Narratives](https://longbridge.com/en/news/286343743.md)
*2026-05-14T02:06:44.000Z*
> Legend Biotech (LEGN) reported Q1 2026 revenue of $305.1 million, with a basic EPS loss of $0.29 and a net loss of $54.3

### [These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results](https://longbridge.com/en/news/286301750.md)
*2026-05-13T18:07:03.000Z*
> Legend Biotech (LEGN) reported Q1 losses of 3 cents per share and sales of $305.1 million, missing estimates. Despite th

### [Legend Biotech Q1 Solid for Carvykti, Focus Shifts to In Vivo Pipeline, RBC Says](https://longbridge.com/en/news/286290495.md)
*2026-05-13T15:43:00.000Z*
> Legend Biotech reported a strong Q1 for Carvykti, with $597 million in sales, driven by increased use in therapy lines a

### [Barclays Reaffirms Their Buy Rating on Legend Biotech (LEGN)](https://longbridge.com/en/news/286227290.md)
*2026-05-13T08:55:42.000Z*
> Barclays analyst Etzer Darout has reaffirmed a Buy rating on Legend Biotech (LEGN) with a price target of $80.00. Darout

### [Brief News: Legend Biotech's Revenue Soars, Sales Momentum for Cancer Therapies Continues to Strengthen](https://longbridge.com/en/news/286208783.md)
*2026-05-13T06:35:46.000Z*
> Legend Biotech's revenue in the first quarter increased by 56% year-on-year, reaching USD 305.1 million, mainly due to s

### [Legend announced the closure of its business and will cease operations on July 12](https://longbridge.com/en/news/286188203.md)
*2026-05-13T03:05:18.000Z*
> Legend announced that it will close its business on July 12 and gradually cease company and product services. Despite ga

### [Legend Biotech (NASDAQ:LEGN) Announces Quarterly Earnings Results](https://longbridge.com/en/news/286138504.md)
*2026-05-12T17:39:50.000Z*
> Legend Biotech (NASDAQ:LEGN) reported quarterly earnings of ($0.03) per share, missing estimates of ($0.02). Revenue was

### [Understanding the Market | GENSCRIPT BIO rises over 5%, joint venture Legend Biotech narrows first-quarter losses, CARVYKTI® net sales increase by 60%](https://longbridge.com/en/news/286178865.md)
*2026-05-13T01:37:03.000Z*
> GENSCRIPT BIO rose over 5%, as of the time of writing, up 5.03%, reported at HKD 15.23, with a trading volume of HKD 29.

### [GENSCRIPT BIO's joint venture Legend Biotech's first-quarter loss narrowed to USD 54.3 million, with earnings per share falling short of expectations](https://longbridge.com/en/news/286174837.md)
*2026-05-13T00:50:00.000Z*
> GENSCRIPT BIO announced that its joint venture company Legend Biotech reported a first-quarter loss of USD 54.3 million